BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2020

ROCKVILLE, Md.–()–BIOQUAL, Inc. (OTC Pink: BIOQ) (www.bioqual.com):

   

 

Nine Months Ended

 

Three Months Ended

 

February 29,

 

February 28,

 

February 29,

 

February 28,

 

 

2020

 

 

2019

 

 

2020

 

 

2019

Revenue

$

32,884,055

 

$

27,922,919

 

$

11,593,217

 

$

9,908,572

Income Before Income Tax

$

4,150,830

 

$

2,357,260

 

$

1,018,306

 

$

658,274

Net Income

$

2,936,730

 

$

1,667,760

 

$

720,406

 

$

465,774

Basic Earnings per Share

    of Common Stock

 

$

 

3.29

 

 

$

 

1.87

 

 

$

 

.81

 

 

$

 

.52

Diluted Earnings per Share

    of Common Stock

 

$

 

3.29

 

 

$

 

1.87

 

 

$

 

.81

 

 

$

 

.52

Weighted Average

    Number of Shares Outstanding

    For Basic Earnings Per Share

 

 

 

 

 

893,416

 

 

 

 

 

 

893,416

 

 

 

 

 

 

893,416

 

 

 

 

 

 

893,416

Weighted Average

    Number of Shares Outstanding

    For Diluted Earnings Per Share

 

 

 

 

 

893,843

 

 

 

 

 

 

893,642

 

 

 

 

 

 

893,843

 

 

 

 

 

 

893,642

         

For more detail related to the fiscal year 2020 unaudited second quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

Source

About the Author: Biotech Today

You might like